Advisornet Financial’s Nektar Therapeutics NKTR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-11,381
Closed -$2.93M 1964
2021
Q2
$2.93M Buy
11,381
+2,729
+32% +$755K 0.19% 118
2021
Q1
$2.6M Buy
8,652
+44
+0.5% +$13.7K 0.18% 127
2020
Q4
$2.19M Buy
8,608
+611
+8% +$158K 0.18% 122
2020
Q3
$1.99M Sell
7,997
-1,358
-15% -$427K 0.17% 132
2020
Q2
$3.25M Sell
9,355
-33
-0.4% -$10.3K 0.26% 88
2020
Q1
$2.51M Buy
9,388
+149
+2% +$46.1K 0.23% 96
2019
Q4
$2.99M Buy
9,239
+6,797
+278% +$1.97M 0.25% 90
2019
Q3
$667K Sell
2,442
-2,992
-55% -$1.1M 0.06% 281
2019
Q2
$2.9M Buy
5,434
+485
+10% +$243K 0.32% 71
2019
Q1
$2.49M Buy
4,949
+845
+21% +$501K 0.3% 75
2018
Q4
$2.02M Sell
4,104
-203
-5% -$123K 0.28% 85
2018
Q3
$3.94M Buy
4,307
+2,707
+169% +$2.31M 0.5% 36
2018
Q2
$1.17M Sell
1,600
-216
-12% -$249K 0.16% 127
2018
Q1
$2.89M Buy
1,816
+1,507
+488% +$1.94M 0.4% 48
2017
Q4
$277K Buy
+309
New +$183K 0.04% 300

Other funds holding NKTR

Advisornet Financial's NKTR Position: Q3 2021 in Review

Advisornet Financial sold out of Nektar Therapeutics (NKTR) in Q3 2021, closing a stake of 11,381 shares — an estimated $2.93M sold.

Advisornet Financial first reported a position in NKTR in Q4 2017 and held it in 15 quarters. The position peaked at $3.94M in Q3 2018. 240 funds tracked by Wall St. Rank hold NKTR as of Q3 2021.

  • Advisornet Financial reported no remaining Nektar Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Advisornet Financial sold 11,381 Nektar Therapeutics shares in Q3 2021, an estimated $2.93M.
  • Advisornet Financial first reported a position in Nektar Therapeutics in Q4 2017 and held it in 15 quarters.
  • Advisornet Financial's Nektar Therapeutics position peaked at $3.94M in Q3 2018.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2021.

Based on Advisornet Financial's 13F filing for Q3 2021, filed 15 Oct 2021.